7 recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 7 |
| Phase 2 | 4 | Recruiting 4 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. AK1967 (Invobenitug also known as Procizumab), Placebo - Shock, Cardiogenic | Phase 1 / Phase 2 | Recruiting | 4TEEN4 Pharmaceuticals GmbH | 90 | 2025-07-13 | 2026-09-14 |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study Methylene Blue - Cytokine Release Syndrome, ICANS | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2025-06-28 | 2025-09-11 |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome | Phase 1 | Recruiting | Taylor Brooks | 20 | 2025-01-14 | 2026-06-25 |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg - Cytokine Release Syndrome | Phase 1 / Phase 2 | Recruiting | CytoAgents, Inc. | 54 | 2023-12-28 | 2026-08-31 |
| Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Packed Red Blood Cells (PRBCs) - Cardiogenic Shock, Extracorporeal Membrane Oxygenation | Phase 1 | Recruiting | University Hospital, Lille | 236 | 2023-09-18 | 2026-09-17 |
| Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2) Allogeneic thyTreg 5.000.000, Allogeneic thyTreg 10.000.000 - Systemic Inflammatory Response Syndrome | Phase 1 / Phase 2 | Recruiting | Hospital General Universitario Gregorio Marañon | 24 | 2023-06-27 | 2026-09-18 |
Cytokine Release Syndrome (4) · COVID-19 (2) · Shock, Cardiogenic (2) · Systemic Inflammatory Response Syndrome (2) · Anemia (1) · Influenza, Human (1) · Lung Diseases (1) · Lymphoma, Non-Hodgkin (1) · Pneumonia (1) · Respiratory Distress Syndrome (1) · Respiratory Syncytial Virus Infections (1)
Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Inflammation (5) · Systemic Inflammatory Response Syndrome (3) · Cardiovascular Diseases (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Heart Diseases (2) · Hemic and Lymphatic Diseases (2) · Infarction (2) · Infections (2) · Ischemia (2) · Myocardial Infarction (2) · Myocardial Ischemia (2)
Gemcitabine (1) · Methylene Blue (1) · Oxaliplatin (1) · Saline Solution (1) · Therapeutics (1) · procizumab (1) · siltuximab (1)
4TEEN4 Pharmaceuticals GmbH (1) · CytoAgents, Inc. (1) · Hospital General Universitario Gregorio Marañon (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · PEACHES BIOTECH (1) · Taylor Brooks (1) · University Hospital, Lille (1)
Spain (3) · France (2) · United States (2) · Armenia (1) · Belgium (1) · China (1) · Czechia (1) · Germany (1) · Netherlands (1) · Poland (1) · Serbia (1)
Alexandre Mebazaa, Professor (1) · David A. Morrow, MD, MPH (1) · David Bernal, Dr. (1) · Jianxiang Wang (1) · Mike Howell, PhD (1) · Rafael Correa-Rocha, PhD (1) · Taylor Brooks, MD (1)
PMID 20236457, PMID 21325598, PMID 23594433, PMID 24300013, PMID 24691607, PMID 25805204, PMID 26443879, PMID 26836806, PMID 28131429, PMID 30181084, PMID 30444173, PMID 30860564, PMID 31723612, PMID 33475735, PMID 35454123, PMID 42165327, PMID 9971864
2023 (1), R44CA295189 (1)